The Price Effects of Biosimilars in the United States
Value in Health · 2025
DOI: 10.1016/j.jval.2025.02.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Value in Health, 2025. Verfasst von Mireia Jofre-Bonet und 4 weiteren Autor:innen. Beteiligte Einrichtung: Office of Health Economics, London, England, UK; City St George's, University of London, London, England, UK. Electronic address: mjofre-bonet@ohe.or…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Economic Competition, Drug Costs. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: Pfizer Inc.
Abstract (Originalsprache)
OBJECTIVES: This study evaluates the impact of biosimilar competition on the price of reference products and biosimilars in the US pharmaceutical market. We focus on average sales price (ASP) dynamics since 2015 in Medicare Part B because Medicare is a critical payer stakeholder in biosimilar price dynamics. METHODS: Using Centers for Medicare and Medicaid Services data over 34 quarters beginning in 2015, we analyzed the price effects of biosimilar competition in 8 biologic product markets. First, we evaluated the effect of biosimilar competition on ASP. Second, we evaluated the effect of market concentration on ASP using the Herfindahl-Hirschman index. We used instrumental variable methods to address the endogeneity between competition and ASP. Across analyses, our outcome variable is price ratio-the ratio of ASP measured over time relative to the fixed ASP at study baseline. RESULTS: Our results showed a 10% to 13% decrease in the originator price ratio for entry of each additional biosimilar competitor, and a 1.8% decrease in the originator price ratio with a 10% decrease in market concentration at the lowest Herfindahl-Hirschman index observed in study period. These findings highlight the statistically significant effect of biosimilar competition and market concentration on prices in high-cost biologics drug markets. CONCLUSIONS: Our findings demonstrate that the US biosimilars market has become highly competitive, and as a result, prices have declined significantly over the period 2015 to 2023. These price dynamics have generated substantial savings for Medicare; however, there is a potential threat to market sustainability if these price trend dynamics persist in the coming years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Health Economics, London, England, UK; City St George's, University of London, London, England, UK. Electronic address: mjofre-bonet@ohe.org.
- London School of Economics and Political Sciences, London, England, UK.
- CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA; Curta, Inc, Seattle, WA, USA.
- CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA; Pfizer Inc, New York, NY, USA.
- London School of Economics and Political Sciences, London, England, UK; CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA; Curta, Inc, Seattle, WA, USA.
Förderung
- Pfizer Inc
Zitieren
APA
Jofre-Bonet, M., McGuire, A., Dayer, V., Roth, J. A., & Sullivan, S. D. (2025). The Price Effects of Biosimilars in the United States. Value in Health. https://doi.org/10.1016/j.jval.2025.02.008
Vancouver
Jofre-Bonet M, McGuire A, Dayer V, Roth JA, Sullivan SD. The Price Effects of Biosimilars in the United States. Value in Health. 2025. doi:10.1016/j.jval.2025.02.008
BibTeX
@article{JofreBonet2025,
author = {Jofre-Bonet, Mireia and McGuire, Alistair and Dayer, Victoria and Roth, Joshua A and Sullivan, Sean D},
title = {The Price Effects of Biosimilars in the United States},
journal = {Value in Health},
year = {2025},
doi = {10.1016/j.jval.2025.02.008}
}
EUVIMED